Historic Investment Portfolio

Exits via M&A

M&A

  • Afferent (acquired by Merck)
  • Alios (acquired by Johnson+Johnson)
  • Ambit (acquired by Daiichi Sankyo)
  • Ambrx (acquired by Wuxi)
  • Artus (acquired by Qiagen)
  • BioFire (acquired by bioMérieux)
  • BioXell (acquired by Cosmo)
  • CGI (acquired by Gilead)
  • DVS (acquired by Fluidigm)
  • Envoy (acquired by Takeda)
  • Foundation (acquired by Roche)
  • HistoRx (acquired by Genoptix)
  • Leukosite (acquired by Millennium)
  • Memory (acquired by Roche)
  • Miikana (acquired by EntreMed)
  • Sequana (acquired by Celera)
  • Syrrx (acquired by Takeda)
  • Tripath (acquired by Becton Dickinson)

Historic Investment Portfolio

Exits via IPO

IPOs

  • Addex
  • Anadys
  • Caliper
  • Complete Genomics
  • CV Therapeutics
  • deCode
  • Fibrogen, Inc
  • Foundation Medicine
  • Halozyme Therapeutics
  • Horizon Discovery
  • Pharmasset
  • Protein Design Labs, Inc
  • Taimed
  • TiGenix